Key facts
- Atransen Pharma’s last known valuation is $6.5M (May 2025).
- It has raised $7.8M; the latest was Accelerator/Incubator in Sep 2025.
- Notable investors include Berkeley SkyDeck, Angel Bridge, Osaka University Venture Capital, Jafco, LINK-J.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Atransen Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Atransen Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Atransen Pharma
Operator of a drug discovery venture company intended to develop drugs that would pave the way for a new era of cancer treatment. The company provides patients with treatments that suppress the growth of cancer cells and have fewer side effects, and focus is on LAT1 large neutral amino acid transporter.
- Sector
- Healthcare
- HQ
- Osaka, Japan
- Founded
- 2022
- Employees
- 2
- Website
- atransen.com/
- Ownership
- Privately Held (backing)
Atransen Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atransen Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atransen Pharma in its N-PORT filings yet. We sweep new filings monthly.